This page shows what was measured, who it was measured in, and what that does not settle.
What Plerixafor does in the body
Plerixafor injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
From the FDA-approved label: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules. Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans.
Why people take it. Plerixafor injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · S915P5499N · read 2026-08-29
Its recorded molecular formula is C28H54N8, weighing 502.79 g/mol.
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 175 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.
✗ The study did not show it
Who was studied
NCT00103662
How many people
302
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis
✗ The study did not show it
Who was studied
NCT00103610
How many people
298
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
In phase II, avoidance rate of grade III-IV acute GVHD at day +100
✗ The study did not show it
Who was studied
NCT05470491
How many people
265
Study design
Phase 1/Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Pre-Apheresis Peripheral Blood CD34+ Cell Count
✗ The study did not show it
Who was studied
NCT07423728
How many people
160
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
the proportion of patients achieving ≥2 × 10ˆ6/kg CD34+ HSCs within ≤4 apheresis sessions.
✗ The study did not show it
Who was studied
NCT05510544
How many people
140
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of patients achieving a sufficient number of stem cells
✗ The study did not show it
Who was studied
NCT03442673
How many people
137
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Subcutaneous
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Plerixafor injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of plerixafor have not been established in pediatric patients.”
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
On older people, the label states: “Of the total number of subjects in controlled clinical studies of plerixafor, 24% were 65 and over, while 0.8% were 75 and over.”
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Limited available data with plerixafor use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.”
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
On people who are breastfeeding, the label states: “8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating plerixafor [ see Use in Specific Populations (8.1) ] .”
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
On people with reduced kidney function, the label states: “In patients with moderate and severe renal impairment (CL CR less than or equal to 50 mL/min), reduce the dose of plerixafor by one-third to 0.16 mg/kg [ see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].”
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Sold as solution, injection, solution, injection, given by the subcutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Subcutaneous
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
19 products list this as an active ingredient in the United States drug directory. 19 of them contain it and nothing else.
FDA National Drug Code directory · 70710-1208 · read 2026-08-29
They are sold as injection, injection, solution, powder and solution, taken subcutaneous.
FDA National Drug Code directory · 70710-1208 · read 2026-08-29
The regulator's established pharmacologic class for it is hematopoietic stem cell mobilizer [epc] and increased hematopoietic stem cell mobilization [pe].
FDA National Drug Code directory · 70710-1208 · read 2026-08-29
13 published labels name it as an active ingredient. 13 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-29
Plerixafor is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: 24 mg/1.2 mL (20 mg/mL) sterile, clear, colorless to pale-yellow solution in a single-dose vial., recorded as fda label in effect 2024-08-27 in the United States.
US prescribing information · f26effc5-2a22-441f-91ac-e131ee1c9886 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Plerixafor studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Plerixafor are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
12 documents were read for this substance.
RNAWiki source record
12 of them state the same halfLife, and they agree.
RNAWiki source record
12 of them state the same proteinBinding, and they agree.
RNAWiki source record
12 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
S915P5499N
RxNorm concept
828700
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
10 approved applications cover products containing this substance. The earliest was NDA022311, approved 20081215 to GENZYME.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q2
On the Plerixafor label: indicated for what?
"Plerixafor injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM). Plerixafor injection, a hematopoietic stem cell…": indications and usage on Plerixafor's label. DailyMed label · b42fda2a-80c8-4bdd-a91d-03d11bef064a · 2026-05-06
Q3
148 registered trials of Plerixafor — at which phases?
Registered studies posting no result
93 of 148
148 registered studies of Plerixafor: 86 phase2, 70 phase1, 8 na or unstated, 6 phase3, 5 na, 3 phase4, 1 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
132 with a PubMed record
Show the evidence
phase2
86
phase1
70
na or unstated
8
phase3
6
na
5
phase4
3
11 more recorded rows
early phase1
1
completed
89
terminated
21
recruiting
12
unknown
8
withdrawn
8
active not recruiting
5
not yet recruiting
2
approved for marketing
1
enrolling by invitation
1
no longer available
1
recorded 2026-09-01 · last checked 2026-09-04
Q4
28 of Plerixafor's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?
safety (5), futility/efficacy (1), accrual/recruitment (13), funding/business (4) and other (5): Plerixafor's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Enrollment terminated in 2005 to focus on Phase 3 study enrollment."; 28 of 148 registered studies
Show the evidence
Trial
NCT00395967
terminated; "Enrollment terminated in 2005 to focus on Phase 3 study enrollment."
NCT00396383
terminated; "Insufficient cell mobilization for tandem transplants"
NCT00669669
terminated; "Terminated due to loss in funding."
NCT01027923
terminated; "Withdrawal of support from sponsor"
NCT01076270
terminated; "Funding withdrawal"
NCT01160354
terminated; "Slow Accrual"
14 further recorded trials
NCT01301963
terminated; "Slow Accrual"
NCT01331018
terminated; "Study ended early due to end of funding."
NCT01339039
terminated; "Low accrual rate"
NCT01353937
withdrawn; "Never Activated"
NCT01408043
terminated; "Slow Accrual"
NCT01610999
terminated; "Unavailability of study article"
NCT01621477
terminated; "Study was terminated in August 2016 due to replacement by a new study."
NCT01655875
terminated; "lack of patient enrollment"
NCT01746173
terminated; "Slow accrual and futility"
NCT02343666
withdrawn; "Administrative closure prior to any enrollments"
NCT02682953
withdrawn; "subject recruitment not feasible due to standard care changes"
NCT02750254
terminated; "Toxicity. Only enrolled patients in phase I portion of trial."
NCT02790957
terminated; "Safety reasons"
NCT03240861
terminated; "slow accrual"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Plerixafor used Plerixafor 0.12 mg/kg — over how long?
studies of Plerixafor used the recorded amount. ClinicalTrials.gov · 2026-09-01
1 recorded entry; human; also "Plerixafor 0.12 mg/kg"
Show the evidence
humanNCT03244930
Plerixafor 0.12 mg/kg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Plerixafor's half-life is 0.3 hours — which schedules were studied?
0.3 hours, the half-life Plerixafor's label states: "The distribution half-life (t 1/2α ) was estimated to be 0.3 hours and the terminal population half-life (t 1/2β ) was 5.3 hours in patients with normal renal function." DailyMed label · b42fda2a-80c8-4bdd-a91d-03d11bef064a · 2026-05-06
tmax 30 to 60 minutes.
Show the evidence
half lifepharmacokinetics
0.3 hours; The distribution half-life (t 1/2α ) was estimated to be 0.3 hours and the terminal population half-life (t 1/2β ) was 5.3 hours in patients with normal renal function.
tmaxpharmacokinetics
30 to 60 minutes; Absorption Peak plasma concentrations occurred at approximately 30 to 60 minutes after a SC dose.
metabolismpharmacokinetics
Metabolism The metabolism of plerixafor was evaluated with in vitro assays.
recorded 2026-05-06 · last checked 2026-09-04
Q7
Which running trial of Plerixafor could settle lifespan?
NCT02570542 measures progression-free survival (PFS), reading out 2026-10.
4 open trials; n 59; "Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma…"
Show the evidence
Trial
NCT02570542
"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)"; n 59; "progression-free survival (PFS)"; 2026-10
NCT05088356
"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft"; n 66; "Determine the GVHD-free relapse-free survival (GRFS) post-HCT ( Arm-A)"; 2028-05
NCT02015013
"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models"; n 40; "To mobilize CD34+ HPCs in ICL patients and healthy volunteers for collection and transfer into immunocompromised mice to investigate thymic development, survival, and trafficking of these cells in murine lymphoid and non-lymphoid organs"; 2030-10-31
NCT07605416
"Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial"; n 74; "Overall survival (OS)"; 2032-11-06
Q8
Which 43 trials of Plerixafor posted no result?
Posted no result
43 of 43 completed trials
Registrations
NCT00665314, NCT00741780, NCT00694590, NCT00741325, NCT01579149 and NCT00990054, and 37 more
Completion dates
oldest 2009-06; newest 2024-08-28
Show the evidence
Trial
NCT00665314
2009-06
NCT00741780
2011-07
NCT00694590
2011-09
NCT00741325
2011-11
NCT01579149
2012-02
NCT00990054
2012-03
14 further recorded trials
NCT01700608
2012-04
NCT01738373
2012-11
NCT01074060
2013-02
NCT01802892
2013-04-02
NCT01037517
2013-08
NCT01068301
2013-10
NCT01236144
2014-01
NCT01141543
2014-05
NCT02056210
2014-10
NCT01767714
2014-11
NCT01206075
2014-12
NCT00322127
2015-01-23
NCT01164345
2015-05
NCT02221479
2015-07
Q9
At the median, Plerixafor's trials enrolled 23.5 people — anything larger?
Median enrolment
23.5
Largest enrolment
302
Registered trials counted
146
Q10
What do 205 spontaneous reports say about Plerixafor — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Plerixafor appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 205 reaction mentions were counted: febrile neutropenia 50; mucosal inflammation 30; pyrexia 29; thrombocytopenia 24. FAERS via Open Targets · CHEMBL18442 · 2026-06-24
Show the evidence
febrile neutropenia
50
mucosal inflammation
30
pyrexia
29
thrombocytopenia
24
neutropenia
17
pleural effusion
12
4 more recorded rows
bone pain
11
cytomegalovirus infection
11
herpes simplex
11
organising pneumonia
10
recorded 2026-06-24 · last checked 2026-09-04
Q11
Which 10 reactions does Plerixafor's label not list?
Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5).
pharmacokinetics
In in vitro studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, or CYP3A4 enzymes.
pharmacokinetics
These findings suggest that plerixafor has a low potential for involvement in cytochrome P450 dependent drug-drug interactions.
pharmacokinetics
At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study with MDCKII and MDCKII-MDR1 cell models.
clinical_pharmacology
Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5).
clinical_pharmacology
In in vitro studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, or CYP3A4 enzymes.
2 more recorded rows
Interaction statementclinical_pharmacology
These findings suggest that plerixafor has a low potential for involvement in cytochrome P450 dependent drug-drug interactions.
Interaction statementclinical_pharmacology
At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an in vitro study with MDCKII and MDCKII-MDR1 cell models.
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.